PATHWAY AVID

K111726 · Custom Spine, Inc. · MAX · Feb 6, 2012 · Orthopedic

Device Facts

Record IDK111726
Device NamePATHWAY AVID
ApplicantCustom Spine, Inc.
Product CodeMAX · Orthopedic
Decision DateFeb 6, 2012
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 888.3080
Device ClassClass 2
AttributesTherapeutic

Intended Use

The PATHWAY AVID intervertebral body fusion device is intended for spinal fusion procedures at one or two contiguous levels (L2-S1) in skeletally mature patients with degenerative disc disease (DDD). DDD is defined as back pain with discogenic origin with degeneration of the disc confirmed by the history and radiographic studies. DDD patients may also have Grade I Spondylolisthesis at involved levels. The patients may have had a previous non-fusion spinal surgery at the involved level(s). The device is intended to be used with supplemental fixation systems that have been cleared for the lumbosacral spine (i.e. posterior pedicle screws and rod systems and anterior screw and rod systems). The device is intended to be used with autogenous bone graft. Patients must have undergone a regimen of at least six (6) months of non-operative treatment prior to being treated with the PATHWAY AVID device. The PATHWAY AVID Intervertebral body fusion device must be inserted from a transforaminal approach (TLIF).

Device Story

Intervertebral body fusion device; PEEK spacer with metallic hinges/linkages; inserted via transforaminal approach (TLIF) by surgeons; used with autogenous bone graft and supplemental fixation (pedicle screws/rods). Provides structural support for spinal fusion in DDD patients. Modification introduces MP35N (Co-Cr-Ni-Mo) alloy as alternative to titanium for hinges/linkages. Device maintains PEEK spacer structure; provides mechanical stability during fusion process.

Clinical Evidence

Bench testing only. Tensile testing compared linkage/hinge pins of modified device to predicate; results show equivalence. Corrosion testing performed per ASTM F2129-08 demonstrated acceptable corrosion resistance.

Technological Characteristics

PEEK (ASTM F2026) spacer; hinges/linkages made of either Titanium (ASTM F136) or MP35N (ASTM F562). Transforaminal (TLIF) form factor. Mechanical fixation via hinge/linkage system. No software or electronic components.

Indications for Use

Indicated for skeletally mature patients with degenerative disc disease (DDD) at one or two contiguous levels (L2-S1), including those with Grade I Spondylolisthesis or retrolisthesis and prior non-fusion surgery. Requires 6 months of failed non-operative treatment.

Regulatory Classification

Identification

An intervertebral body fusion device is an implanted single or multiple component spinal device made from a variety of materials, including titanium and polymers. The device is inserted into the intervertebral body space of the cervical or lumbosacral spine, and is intended for intervertebral body fusion.

Special Controls

*Classification.* (1) Class II (special controls) for intervertebral body fusion devices that contain bone grafting material. The special control is the FDA guidance document entitled “Class II Special Controls Guidance Document: Intervertebral Body Fusion Device.” See § 888.1(e) for the availability of this guidance document.(2) Class III (premarket approval) for intervertebral body fusion devices that include any therapeutic biologic (e.g., bone morphogenic protein). Intervertebral body fusion devices that contain any therapeutic biologic require premarket approval. (c) *Date premarket approval application (PMA) or notice of product development protocol (PDP) is required.* Devices described in paragraph (b)(2) of this section shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.

Predicate Devices

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ FEB - 6 2012 # Section VII. 510(K) SUMMARY ### Date Prepared February 3, 2012 #### Name of Firm Custom Spine, Incorporated 1140 Parsippany Blvd, Suite 201 Parsippany, NJ 07054 Phone: (973) 808-0019 Fax: (973) 808-0707 ## Official Correspondent David Brumfield Senior VP of Research and Development, Quality, and Regulatory 1140 Parsippany Blvd, Suite 201 Parsippany, NJ 07054 Phone: (973) 265-5043 Fax: (973) 808-0707 E-mail: dbrumfield@customspine.com # Establishment Number 3005129649 #### Device Name Legally Marketed Trade Name: PATHWAY AVID Common Name: Intervertebral Body Fusion Device Device Classification: Class II Regulation Number: 21 CFR 888.3080 Device Product Codes: MAX Predicate Devices PATHWAY AVID K090566 ### Description of Modified Device The proposed modification subject device is to be provided to the users in one of two configurations: the predicate device containing PEEK Optima LT1with titanium hinges {1}------------------------------------------------ and linkages (Ti-6Al-4V, ASTM F136) or the proposed PEEK Optima LT1 with MP35N (Co-Cr-Ni-Mo Alloy, ASTM F562). #### Indications for Use The PATHWAY AVID intervertebral body fusion device is intended for spinal fusion procedures at one or two contiguous levels (L2-S1) in skeletally mature patients with degenerative disc disease (DDD). DDD is defined as back pain with discogenic origin with degeneration of the disc confirmed by the history and radiographic studies. DDD patients may also have Grade I Spondylolisthesis at involved levels. The patients may have had a previous non-fusion spinal surgery at the involved level(s). The device is intended to be used with supplemental fixation systems that have been cleared for the lumbosacral spine (i.e. posterior pedicle screws and rod systems and anterior screw and rod systems). The device is intended to be used with autogenous bone graft. Patients must have undergone a regimen of at least six (6) months of non-operative treatment prior to being treated with the PATHWAY AVID device. The PATHWAY AVID Intervertebral body fusion device must be inserted from a transforaminal approach (TLIF). ### Materials This product is manufactured from PEEK (Polyetheretherketone) as per ASTM F2026 and contains either titanium (Ti-6Al-4V, ASTM F136) marker and linkages or MP35N (Co-Cr-Ni-Mo, ASTM F562) markers and linkages. #### Performance Data Tensile testing of the linkages was conducted comparing the predicate AVID Interbody Fusion Device (K090566) and the proposed modification. This mechanical data indicates that the linkage and hinge pins with the proposed modification show equivalence to the titanium linkages and hinge pins of the predicate. Previous mechanical testing conducted on the predicate (K090566) demonstrated that the failure modes were in the PEEK spacer, and not the linkage or hinge pins. Corrosion testing was performed on the linkage system and the hinge pins in accordance with ASTM F 2129-08 "Standard Test Method for Conducting Cyclic Potentiodynamic Polarization Measurements to Determine the Corrosion Susceptibility of Small Implant Devices". The data demonstrates that these devices display acceptable corrosion resistance in the ASTM F 2129 test. See complete test report in Section 2 of the Response to FDA Deficiency letter of 07 October 2011. {2}------------------------------------------------ # Substantial Equivalence Statement Custom Spine believes that the proposed addition to the PATHWAY AVID family has the same indications for use, same technological characteristics, same design, and the same interbody material (PEEK) structure. {3}------------------------------------------------ Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized eagle or bird-like symbol with three curved lines representing its body and wings. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular fashion around the bird symbol. Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002 FEB - 6 2012 Custom Spine, Inc. % Mr. David Brumfield Senior Vice President of Research and Development, Quality and Regulatory 1140 Parsippany Boulevard, Suite 201 Parsippany, New Jersey 07054 Re: K111726 Trade/Device Name: PATHWAY AVID Regulation Number: 21 CFR 888.3080 Regulation Name: Intervertebral body fusion device Regulatory Class: Class II Product Code: MAX Dated: January 27, 2012 Received: February 01, 2012 Dear Mr. Brumfield: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be fround in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. {4}------------------------------------------------ Page 2 - Mr. David Brumfield Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's-Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Sincerely yours, Mark N. Melkerson Director Division of Surgical, Orthopedic and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {5}------------------------------------------------ # Section VII. Indications for Use 510(k) Number (if known): LL | | |22 Device Name: PATHWAY AVID The PATHWAY AVID Intervertebral body fusion device is intended for spinal fusion procedures at one or two contiguous levels (L2-Sl) in skeletally mature patients with degenerative disc disease (DDD). DDD is defined as back pain of discogenic origin with degeneration of the disc confirmed by the history and radiographic studies. DDD patients may also have up to Grade I Spondylolisthesis or retrolisthesis at the involved levels. The patient may have had a previous non-fusion spinal surgery at the involved level(s). The device is intended to be used with supplemental spinal fixation systems that have been cleared for lumbosacral spine (i.e. posterior pedicle screws and rods systems and anterior screw and rod systems). The device is intended to be used with autogenous bone graft. Patients must have undergone a regimen of at least six (6) months of non-operative treatment prior to being treated with the PATHWAY AVID device. The PATHWAY AVID Intervertebral body fusion device must be inserted using a transforaminal approach. Prescription Use (Part 21 CFR 801 Subpart D) AND/OR Over-The-Counter Use (21 CFR 807 Subpart C) | (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) | | |--------------------------------------------------------------------------|--| |--------------------------------------------------------------------------|--| Concurrence of CDRH, Office of Device Evaluation (ODE) Signature (Division Sign . . ) Division of Surgical, Orthopedic, and Restorative Devices K111726 510(k) Number_________________________________________________________________________________________________________________________________________________________________
Innolitics

Panel 1

/
Sort by
Ready

Predicate graph will load when search results are available.

Embedding visualization will load when search results are available.

PDF viewer will load when search results are available.

Loading panels...

Select an item from Submissions

Click any panel, subpart, regulation, product code, or device to see details here.

Section Matches

Results will appear here.

Product Code Matches

Results will appear here.

Special Control Matches

Results will appear here.

Loading collections...